Xerion Pharmaceuticals Acquires Rights to Tufts Cancer Targets | GenomeWeb

NEW YORK, Feb. 26 – Xerion Pharmaceuticals has acquired exclusive rights to cancer targets identified by a Tufts University scientist, the company said today.

The Martinsried, Germany-based firm, in a statement, said it will use the targets to create therapeutic antibodies. The targets were identified in the lab of Daniel Jay, a professor of physiology at Tufts.

Financial details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.